TY - JOUR AU - Al-Rawi, Mahmood Basil A. PY - 2023/03/15 Y2 - 2024/03/29 TI - COVID-19 Versus Diabetes Mellitus: Whom Affect the Other? JF - Asian Journal of Pharmaceutics (AJP) JA - AJP VL - 17 IS - 1 SE - REVIEW ARTICLES DO - 10.22377/ajp.v17i1.4705 UR - https://asiapharmaceutics.info/index.php/ajp/article/view/4705 SP - AB - <p>Diabetes is considered as a precipitating factor for the poor outcomes of COVID-19. Patients with diabetes had<br>a 2.5–3.9 times higher odds of being infected. Viral infection in diabetic patients could be harder to treat due to<br>fluctuations in blood glucose levels. Their compromised immune system leads to a longer duration of recovery.<br>Furthermore, poorly controlled diabetes impairs the immune response to viral infections. C-reactive protein,<br>IL-6, and D-dimer are inflammatory biomarkers elevated among diabetic patients infected with COVID-19.Many<br>scenarios could explain; how could COVID-19 induce Type 1 diabetes? and how COVID-19 brings out Type 2<br>diabetes? There is lack of data regarding pancreatic abnormalities and manifestation in COVID-19 patients.<br>Hence, further investigations are required to stand on the consequences of COVID-19 in subjects with prediabetes<br>and patients with diabetes. Losing at least 15 pounds, regular physical exercise, control diet and regular<br>checkup are the most important measures for prevention of diabetes after COVID-19. Regular monitoring of<br>blood sugar levels after COVID-19 illness and control of hyperglycemia as early as possible are essential to avoid<br>development of severe complications and poor outcome. Appropriate management of comorbidities is of great<br>significance in mitigating the COVID-19 pandemic. Diabetic patients must have priority for vaccination against<br>COVID-19. CDC recommends that people with underlying medical conditions including diabetes should receive<br>a third dose of COVID-19 Vaccine at least 3–6 months after completion of their second dose series.</p> ER -